Evaluation of microvessel density and p53 expression in pancreatic adenocarcinoma

Ricardo Jureidini, I,* José Eduardo Monteiro da Cunha, I Flavio Takeda, I Guilherme Naccache Namur, I Thiago Costa Ribeiro, I Rosely Patzina, II Estela RR Figueira, I Ulysses Ribeiro Jr, I Telesforo Bacchella, I Ivan Cecconello I

Faculdade de Medicina da Universidade de São Paulo, I Departamento de Gastroenterologia. II Departamento de Patologia, São Paulo/SP, Brazil.

OBJECTIVE: To evaluate the prognostic significance of microvessel density and p53 expression in pancreatic cancer.

METHODS: Between 2008 and 2012, 49 patients with pancreatic adenocarcinoma underwent resection with curative intention. The resected specimens were immunohistochemically stained with anti-p53 and anti-CD34 antibodies. Microvessel density was assessed by counting vessels within ten areas of each tumoral section a highpower microscope.

RESULTS: The microvessel density ranged from 21.2 to 54.2 vessels/mm². Positive nuclear staining for p53 was found in 20 patients (40.6%). The overall median survival rate after resection was 24.1 months and there were no differences in survival rates related to microvessel density or p53 positivity. Microvessel density was associated with tumor diameter greater than 3.0 cm and with R0 resection failure.

CONCLUSIONS: Microvessel density was associated with R1 resection and with larger tumors. p53 expression was not correlated with intratumoral microvessel density in pancreatic adenocarcinoma.

KEYWORDS: Pancreatic Neoplasms; Molecular Biology; p53 protein; Prognosis; Microvessel.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDA) is an aggressive carcinoma whose incidence and prevalence have steadily increased over the years. As a result, PDA has become the fourth most common cause of cancer-related death in the western world (1). Pancreatic cancer is also the fourth leading cause of cancer-related mortality in the United States, and in Brazil, the five-year actuarial survival rate is 5% (2). The annual death rate from the disease almost equals its annual incidence due to the aggressive nature of the cancer and the lack of effective means of screening for it during its early, curable stage. Molecular markers and imaging have not proven to be accurate modalities for screening for pancreatic cancer. The diagnosis and management of pancreatic cancer continues to be an overwhelming challenge (3,4).

Surgical treatment of PDA is considered a gold standard procedure as staging permits, but the large majority of patients have tumors that are unresectable at the time of diagnosis. Nevertheless, in the absence of credible alternative cures, surgical resection remains the only option with any potential for curing pancreatic adenocarcinoma, with overall resectability rates ranging from 15% to 20% for all patients, mortality rates ranging from 2 to 5% and total complication rates ranging from 30 to 40% (5).

Angiogenesis is the formation of new blood vessels from a pre-existing vascular network. During the prognostic state of cancer, it has been suggested that oxygen must penetrate 200 μm from a blood vessel to support cell existence and that neovascularization is mandatory for tumor cell survival (6). Some studies (7,8) have correlated microvessel density (MVD) to angiogenesis and the presence of metastasis in the peripheral regions of pancreatic tumors. The p53 tumor suppressor gene seems to regulate angiogenesis to some extent, and p53 mutations have been reported as possible markers for identifying precursor lesions with malignant transformation potential.

The aim of the current study was to determine what type of relationship exists between MVD and p53 expression with respect to patient outcome following surgical treatment of pancreatic adenocarcinoma. Furthermore, we assessed the
correlation between clinicopathological features, MVD and survival outcome in these patients.

**SUBJECTS AND METHODS**

This study was approved by the Research and Ethics Committee of the Faculdade de Medicina da Universidade de São Paulo. Forty-nine patients underwent duodenopancreatectomy with lymphadenectomy and histologically proven pancreatic adenocarcinomas were selected. All patients were surgically treated at the Department of Digestive Surgery, São Paulo School of Medicine and did not receive chemotherapy or anti-angiogenesis therapy before surgery. All patients were followed up and data were collected between 2008 and 2012. The cases included 22 males and 27 females, with a mean age of 58.3 years (Table 1). Paraffin blocks containing fragments of tumor and adjacent epithelia were sectioned, stained with haematoxylin & eosin (H&E), and prepared for histological analysis by light microscopy.

**Immunohistochemical determination of p53 expression**

Paraffin-embedded tissues were used for immunohistochemical analysis of p53 expression. First, sections (2-3 μm) were mounted on microscope slides. Then, the sections were deparaffinized in xylene at 60°C for 30 minutes, followed by treatment with a graded series of alcohol and rehydration. For the deparaffinization, the samples were incubated with hydrogen peroxide in methanol for 20 min to block endogenous peroxidase. The sections were microwaved twice at 500 W for 5 min each time in 10 mmol/L sodium citrate (pH 6.0). The sections were then incubated with antibody against human p53 protein produced from the K0680 clone (DAKO LSAB 

The slides were examined by investigators who were blinded to the corresponding clinicopathologic data. p53 immunoreactivity was assessed as positive only when tumors exhibited intense nuclear staining and the reactivity was categorized as either negative expression (less than 10% positive tumor cells) or positive expression (at least 10% positive tumor cells).

**Quantification of microvessel density**

To quantify microvessel density (MVD) in sections stained for CD34, entire tumor sections were scanned at low power (40x magnification) to identify areas rich in microvessels, which were then counted in ten randomized areas (Figure 1). In each area, individual microvessels were counted under high power (200x magnification) to obtain a vessel count for a hundred randomized defined points. The average vessel count in the 10 randomized areas was taken as the MVD. The vessel count was considered significant when the reticulum was in the same position as the stained endothelial cells.

**Associations with clinicopathological factors**

We next studied the associations between MVD and the following clinicopathological factors: sex, age (52 years old), staging, tumor size, histological type, vascular invasion, margins and survival rates. We also assessed the relationship between p53 expression and the same clinicopathological factors. Finally, we compared the associations identified for MVD and p53.

**Statistical methods**

The univariate association between MVD and each clinicopathological item was analyzed using chi-squared tests and t-tests. To determine independent prognostic factors, a generalized linear model was used. Kaplan-Meyer and Log-Rank tests were applied to assess survival rate. P < 0.05 was considered statistically significant.

**RESULTS**

Of the 49 patients included in the study, forty-six had cephalic pancreatic carcinoma (93.8%). Thirty-one patients (63.2%) were at least stage IIB and 32 (65.3%) patients had tumors that were pT3. Twenty-nine patients (59.2%) had lymph node metastasis, 45 (91.8%) had perineural invasion.

---

**Table 1 - Demographic and clinicopathologic distributions.**

| Variable             | N   | %   |
|----------------------|-----|-----|
| Gender               |     |     |
| Female               | 27  | 55.1%|
| Male                 | 22  | 44.9%|
| Age                  |     |     |
| Mean = 58.3 (40–77 months) |   |     |
| T                    |     |     |
| 1                    | 5   | 10.2%|
| 2                    | 8   | 16.3%|
| 3                    | 32  | 63.3%|
| 4                    | 4   | 8.2% |
| N                    |     |     |
| Negative             | 20  | 40.8%|
| Positive             | 29  | 59.2%|
| Staging              |     |     |
| IA                   | 4   | 8.2% |
| IB                   | 5   | 10.2%|
| IIa                  | 9   | 18.4%|
| IIB                  | 27  | 55.1%|
| III                  | 4   | 8.2% |
| Perineural invasion  |     |     |
| Absent               | 4   | 8.2% |
| Present              | 45  | 91.8%|
| Vascular invasion    |     |     |
| Absent               | 23  | 46.9%|
| Present              | 26  | 53.1%|
| Size                 |     |     |
| Mean = 3.32 (1.5-6.5 cm) |   |     |
| < 3.0 cm             | 18  | 36.7%|
| ≥ 3.0 cm             | 31  | 63.3%|
| Histological type    |     |     |
| Well differentiated   | 23  | 46.9%|
| Moderately differentiated | 19 | 38.8%|
| Undifferentated      | 7   | 14.3%|
| Margins              |     |     |
| Free                 | 30  | 61.2%|
| Compromised          | 19  | 38.8%|
| Vascular resection   |     |     |
| No                   | 39  | 79.6%|
| Yes                  | 10  | 20.4%|
| MVD                  |     |     |
| Mean                 |     |     |
| < 46.2               | 28  | 57.1%|
| ≥ 46.2               | 21  | 42.9%|
| p53                  |     |     |
| Negative             | 29  | 59.2%|
| Positive             | 20  | 40.8%|
and 26 (53.1%) had vascular invasion. The average tumor size was 3.36 cm (1.5 to 6.5 cm).

The mean MVD was 46.2 vessels/mm², and this value was markedly higher in tumors equal to or greater than 3.0 cm in diameter ($p=0.03$) (Table 2).

Table 3 shows the relationships that were identified between p53 and clinicopathological factors; however, no correlations were found.

The generalized linear model analysis of the assessed clinicopathological factors revealed that surgical margin was the only independent factor related to DMV ($p<0.05$).

The actuarial survival rate did not demonstrate any statistically significant differences when compared to the MVD ($p=0.69$) (Figure 2).

### DISCUSSION

In 1971, Folkman formulated the hypothesis that angiogenesis in tumor specimens can be determined by the numbers and structures of blood vessels associated with a tumor and depends on neovascularization, which it is closely associated with tumor growth, staging and prognosis (9,10). In the same way, knowledge regarding the biomolecular mechanisms underlying angiogenesis has enabled efficient inhibition of this process using anti-angiogenic molecules.

Several studies demonstrated that angiogenesis precedes tumor progression and depends on a switch from a pre-vascular to a vascular phase. Recent works have shown that angiogenic factors are already expressed by pre-invasive...
lesions and the induction of angiogenesis is completed during the transition from hyperplasia to neoplasia. This phenomenon is important for invasive cancer screening in high-risk patients. Angiogenesis is also an important aspect of drug delivery for several tumor types (11,12).

Our study indicated that MVD is not correlated with survival prognosis in PDA, a finding that is concordant with results reported by Ellis et al. (13) and Karademir et al. (14). This result likely arose because of the absence of patient selection criteria and the different methodological methods applied (e.g., for vessel counting; Table 4), resulting in diverse MVD values.

In contrast, late diagnosis of tumors and the use of surgical treatment have resulted in advanced staging of PDA. These processes allowed a large number of microvessels to be

Table 3 - Relationships between p53 expression and clinicopathological factors (no correlations were found).

|                      | p53 negative | p53 positive | p   |
|----------------------|--------------|--------------|-----|
| Age                  |              |              |     |
| <52 years            | 7            | 7            | 0.52|
| ≥52 years            | 22           | 13           |     |
| Gender               |              |              |     |
| Male                 | 12           | 15           | 0.04|
| Female               | 17           | 5            |     |
| T                    |              |              |     |
| T1-2                 | 9            | 4            | 0.21|
| T3-4                 | 20           | 16           |     |
| N                    |              |              |     |
| Negative             | 11           | 9            | 0.77|
| Positive             | 18           | 11           |     |
| Size                 |              |              |     |
| <3.0 cm              | 11           | 9            | 0.77|
| ≥3.0 cm              | 18           | 11           |     |
| Histological type    |              |              |     |
| Well and moderately differentiated | 24 | 18 | 0.41 |
| Undifferentiated     | 5            | 2            |     |
| Vascular invasion    |              |              |     |
| Absent               | 14           | 9            | 1.0 |
| Present              | 15           | 11           |     |
| Margins              |              |              |     |
| Free                 | 19           | 11           | 0.55|
| Compromised          | 10           | 9            |     |

Figure 2 - Relationship between overall survival (months) and microvessel density.
Significance of microvessels in pancreatic cancer

Table 4 - Different methods used to count vessels.

| Author           | Year  | Number of patients | Antibody | Number of areas | Type of count | MVD (vessels/mm²) |
|------------------|-------|--------------------|----------|----------------|---------------|------------------|
| Present study    | 2008  | 49                 | CD34     | 10             | Weidner       | 46.2             |
| Takagi           | 2008  | 41                 | CD34     | 3              | Lumen         | 101*             |
| Positano         | 2004  | 137                | CD34     | 5              | Weidner       | 46.2             |
| Nakagawa         | 2002  | 32                 | CD34     | 5              | Weidner       | 3.4#             |
| Niedergheinmann  | 2002  | 70                 | Factor VIII | 3             | Weidner       | 3.4#             |
| Karademir        | 2000  | 22                 | Factor VIII | 6             | Weidner       | 3.4#             |
| Ikeda            | 1999  | 40                 | CD34     | 4              | Weidner       | 3.4#             |
| Fujimoto         | 1998  | 50                 | CD34     | 4              | Weidner       | 3.4#             |
| Ellis            | 1998  | 22                 | Factor VIII | 5             | Weidner       | 3.4#             |

*Only evaluated hypervascularized areas of neoplasm.

#Vessels/mm² – vessels/mm²

identified during tumor analysis and this MVD could not be differentiated between groups. Kuehn et al. (15) demonstrated that a correlation exists between MVD and prognosis; however, over 60% of the patients studied were stage I and therefore had sparser MVD compared to those with advanced tumors.

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer. p53 mutations play a role in determining tumor sensitivity to apoptosis-inducing treatments, such as radiation or cytotoxic drugs (16,17). p53 protein has various important functions in cellular integration, including cell growth control, response to DNA damage, cell-cycle checkpoint control, regulation of transcription and control of genomic stability. It has been suggested that p53 protein may play a role in suppressing angiogenesis (18).

However, in our study, no relationship was identified between p53 and MVD or clinicopathological factors. Overall, MVD analysis can be a useful tool for patient selection when studying angiogenesis inhibition (12,19).

In conclusion, our results demonstrate that MVD is higher in tumors greater than 3.0 cm in diameter and in cases with involved margins. Furthermore, no relationship was found to exist between p53 expression and tumor angiogenesis, MVD or survival rates. Finally, neither MVD nor p53 expression could predict survival in patients with pancreatic adenocarcinoma. There was also no correlation between p53 expression and intratumoral MVD. Finally, MVD analysis is useful for predicting margin involvement.

**AUTHOR CONTRIBUTIONS**

Jureidini R and Cunha JE conceived and designed the study, contributed to data acquisition, analyzed the data and wrote the manuscript. Bachella T and Jureidini R contributed to data acquisition, analyzed the data and wrote the manuscript. Takeda F, Namur GN, Ribeiro TC, Figueira ER and Ribeiro J worked on the pathology studies. All authors read and approved the final manuscript.

**REFERENCES**

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. 2007. CA Cancer J Clin. 2007;57(1):43-66, http://dx.doi.org/10.3322/canjclin.57.1.43.
2. Jureidini, R. Influência da expressão do gene p53 na resposta à quimioterapia FAM para o carcinoma gástrico avançado. ABCD. 2003;16(4):153-8.
3. Schnellldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247(3):456-62, http://dx.doi.org/10.1097/SLA.0b013e3181631342.
4. Lee MX, Sail MW. Screening for early pancreatic ductal adenocarcinoma: an urgent call!. JOP. 2009;10(2):104-8.
5. Gadjojronsson B. Survival statistics gene awry: pancreatic cancer, a case in point. J Clin Gastroenterol. 2002;35(2):180-4, http://dx.doi.org/10.1097/00004836-200208000-00011.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6, http://dx.doi.org/10.1056/NEJM197111282108208.
7. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34(3):337-40, http://dx.doi.org/10.1016/S0959-8049(97)11068-5.
8. Karademir S, Okmen S, Terzi C, Sagol O, Ozer E, Astarcoglu H, et al. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg 2000;7(3):489-95, http://dx.doi.org/10.1007/s005340070020.
9. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol. 2002;8(4):591-5, http://dx.doi.org/10.3748/wjg.v8.i4.591.
10. Takashita R, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology. 2003;64(3):266-74, http://dx.doi.org/10.1159/000069316.
11. Neuzillet C, Tijeras-Raaballan A, Croz J, Faivre S, Hammel P, Raymond E. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32(3-4):385-602, http://dx.doi.org/10.1007/s10555-013-9439-3.
12. Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE. Enhancement of nab-paclitaxel antitumor activity through addition of multtargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther. 2014;13(10):3028-33, http://dx.doi.org/10.1158/1353-7801.MCT-13-0361.
13. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer. 1998;34(3):337-40, http://dx.doi.org/10.1016/S0959-8049(97)11068-5.
14. Karademir S, Sekmen S, Terzi C, Sagol O, Ozer E, Astarcoglu H, et al. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7(3):489-95, http://dx.doi.org/10.1007/s005340070020.
15. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas. 1999;18(1):96-103, http://dx.doi.org/10.1097/00001614-199901000-00012.
16. Mazurek A, Pierzynski P, Kuc P, Kopinski P, Terlikowski S, Nakinska W, et al. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in with endometrial cancer. Neoplasma. 2004;51(1):193-7.
17. Nayak A, Ratle AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, et al. p53 protein alterations in adult astrocytic tumors and oligoden-droglomas. Neurol India 2004; 52: 228-32.
18. Cao W, Chen X, Dai H, Wang H, Shen B, Chu D, et al. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer. 2004;101(4):834-44, http://dx.doi.org/10.1002/cncr.20437.
19. Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, et al. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 2014;6:12, http://dx.doi.org/10.1186/2045-824X-6-12.